Navigation Links
Defeating nicotine's double role in lung cancer
Date:6/8/2009

A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.

The results of the early phase animal model study were reported in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine.

Changes in genes encoding nicotine receptors are strongly associated not only with the tendency to smoke, but with susceptibility to lung cancer. Nicotine exposure also heightens the expression of the nicotine receptors, which leads to increased cell proliferation and inhibition of apoptosis, further setting the stage for cancer.

Patrizia Russo, Ph.D. and Laura Paleari, Ph.D. of the Lung Cancer Unit of the National Cancer Research Institute in Genoa, Italy and colleagues from San Raffaele Pisana Scientific Institute for Research, Hospitalization and Health Care (IRCCS), Catholic University, Campus Biomedico University in Rome, Mario Negri Institute in Milan and CEA Gyf sur Yvette in France showed in past research that an antagonist of nicotine acetylcholine receptors (nAChRs), may serve as an anticancer agent. The antagonist, called d-tubocurarine/α-Cobratoxin (α-CbT), specifically targeted the α7 subunit of nAChRs, the area primarily associated with increased cell proliferation.

In this study, the authors took the research a step further and showed that α-CbT could inhibit non-small cell lung carcinoma (NSCLC) growth and prolong life in non-obese/severe combined immunodeficient (NOD/SCID) mice that had human NSCLC grafted to their lungs. This study attempted to mimic human cancer conditions more closely by delaying treatment until the tumors were well-established. In addition to control mice that were untreated, the researchers randomized one third of the mice to receive standard chemotherapy.

They found that NOD/SCID mice treated with the standard chemotherapy agent, cisplatin, had a 16 percent longer median survival time than untreated mice (p= 0.05). Mice treated with α-CbT, however, had an increased median survival time of 1.7-fold over the cisplatin-treated mice and 2.1-fold over the no-treatment controls (p=0.0005).

"The results of this study show that α-CbT, a powerful, high-affinity α-7-nAChR inhibitor, induces antitumor activity against NSCLC by triggering apoptosis," wrote Dr. Russo. "The prolonged survival of α-CbT-treated animals in our mouse model of NSCLC is most likely the result of several mechanisms, including various antiproliferative and antiangiogenic effects."

The research also found that unaffected (i.e., noncancerous) cells showed no inhibition of proliferation when treated with α-CbT, suggesting that the treatment would have limited if any toxic effects. Dr. Russo and colleagues postulated that this finding may be due to the reduced number of receptor binding sites on normal cells as opposed to cancerous cells. Conversely, they reported that cancer cells with the greatest number of receptor binding sites seemed to respond with the greatest sensitivity to the treatment.

"The goal of this research line is to explore the widest range of possibilities of intervention on the α7-nAChRs. We hope to move further on towards the clinical setting experimentation phase for the assessment of potentially new treatment strategies for NSCLC," said Dr. Russo.

An editorial in the same issue of the journal asked if nicotine may be to lung cancer what estrogen is to breast cancer. Eliot R. Spindel, M.D., Ph.D., of Oregon Health & Science University, stated that estrogen can stimulate the development of breast cancer and estrogen-receptor antagonists, such as tamoxifen, provide therapeutic benefit. In support of a carcinogenic role for estrogen, the incidence of breast cancer appears to be decreasing as estrogen hormone replacement therapy is being used less often. Likewise, nicotine may promote lung cancer yet nicotine receptor antagonists may offer treatment options for patients with lung cancer.

John Heffner, M.D., past president of the ATS stated that "this research clearly has profound clinical implications regarding the role of nicotine in stimulating lung cancer and nicotine receptor antagonists in treating the disease. The highly addictive nature of nicotine, however, complicates patients' ability to quit smoking and avoid ongoing nicotine exposure."

"This [addictive nature of nicotine] underscores the importance of potential FDA regulation of nicotine in tobacco products to limit exposure to this drug that promotes tumor growth," wrote Dr. Spindel.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Kids Brain Trust: A New Nonprofit Gives Parents Hope of Defeating Autism
2. Komen Foundation Support of Planned Parenthood Self-Defeating
3. Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative
4. Mayo Clinic finds new pathology tests double sensitivity to detect bile duct and pancreatic cancers
5. Obesity and diabetes double risk of HF -- patients with both conditions very difficult to treat
6. Indias Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013
7. Decho Doubles Number of Mozy Healthcare Customers
8. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
9. Demand for Outpatient Diagnostic Imaging Forecast to Increase by Double Digits Across All Modalities Through 2012
10. Double-Lung Transplant Better for Long-Term Survival
11. Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area roller derby leagues ... “Make ‘em Bleed,” the most widely attended series of blood drives in California, beginning July ... blood over the past 4 years -- enough to have helped to save up to ...
(Date:7/26/2017)... (PRWEB) , ... July 26, ... ... for Pharmaceutical Engineering (ISPE) will host its 2017 Process Validation and ... concurrent events offer comprehensive solutions to process validation lifecycle challenges faced by ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... has opened in Jupiter. The state of the art center will provide ... treatments with a goal of providing heart patients longer lives. , North American ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... specialty pharmacies, has released an updated version of the HCV Treatment Path app ... treating chronic hepatitis C virus (HCV) infection. All of the latest HCV medications ...
(Date:7/25/2017)... ... July 25, 2017 , ... Creative Pharmacist and ... provide the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND ... ability to develop the Pharmacist eCare Plan, a shared document detailing a patient’s ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
(Date:7/19/2017)... 19, 2017  Mako Medical Laboratories partnered with Secretary ... Family Assistance Fund (MFA) to bring 140 soldiers back ... with their families one last time before being deployed. ... travel and logistics needed for these soldiers. "Mako Medical ... their families. We just wish we could bring them ...
(Date:7/14/2017)... July 13, 2017 It should come as no ... is in the midst of a crippling opioid epidemic. ... 1999, the number of overdose deaths from opiate-based medications has ... half a million dead from 2001 to 2015". During this ... hydrocodone has similarly quadrupled, drawing a compelling link between prescription ...
Breaking Medicine Technology: